Stockscreener 앱 받기
1.09
3.80%
0.04
Prelude Therapeutics Inc 주식(PRLD)의 최신 뉴스
What makes Prelude Therapeutics Incorporated stock price move sharplyJuly 2025 Volume & Free Community Supported Trade Ideas - Newser
Price momentum metrics for Prelude Therapeutics Incorporated explainedJuly 2025 PostEarnings & Consistent Profit Focused Trading Strategies - Newser
Can swing trading help recover from Prelude Therapeutics Incorporated losses2025 Pullback Review & Pattern Based Trade Signal System - Newser
Quantitative breakdown of Prelude Therapeutics Incorporated recent moveMarket Risk Summary & Long-Term Capital Growth Ideas - Newser
Is now a turning point for Prelude Therapeutics IncorporatedEarnings Recap Summary & AI Enhanced Trading Alerts - Newser
Analyzing drawdowns of Prelude Therapeutics Incorporated with statistical tools2025 Technical Overview & Growth Focused Stock Reports - Newser
Prelude Therapeutics Incorporated recovery potential after sell off2025 Breakouts & Breakdowns & Technical Confirmation Alerts - Newser
Chart overlay techniques for tracking Prelude Therapeutics IncorporatedJuly 2025 Earnings & Long Hold Capital Preservation Tips - Newser
Prelude Therapeutics (NASDAQ:PRLD) Given New $3.00 Price Target at JMP Securities - Defense World
Tick level data insight on Prelude Therapeutics Incorporated volatilityWeekly Trade Analysis & Weekly High Conviction Ideas - Newser
Prelude Therapeutics (NASDAQ:PRLD) Trading Up 8.5% – Here’s What Happened - Defense World
Prelude Therapeutics price target lowered to $3 from $4 at Citizens JMP - TipRanks
Will Prelude Therapeutics Incorporated stock go up soon2025 Dividend Review & Community Consensus Trade Alerts - Newser
Has Prelude Therapeutics Incorporated found a price floor2025 AllTime Highs & Safe Entry Point Alerts - Newser
Risk vs reward if holding onto Prelude Therapeutics IncorporatedTrade Exit Summary & Daily Growth Stock Tips - Newser
How to build a dashboard for Prelude Therapeutics Incorporated stockJuly 2025 Market Mood & Target Return Focused Picks - Newser
Prelude Therapeutics Refocuses SMARCA2 Program, Cuts Quarterly Losses - MyChesCo
Best data tools to analyze Prelude Therapeutics Incorporated stockMarket Performance Summary & Advanced Technical Analysis Signals - Newser
Will Prelude Therapeutics Incorporated bounce back from current supportQuarterly Earnings Summary & Weekly Watchlist for Hot Stocks - Newser
Is Prelude Therapeutics Incorporated reversing from oversold territoryNew Guidance & Free Technical Pattern Based Buy Signals - Newser
Does Prelude Therapeutics Incorporated qualify in momentum factor screening2025 Valuation Update & Advanced Technical Analysis Signals - Newser
Is it time to cut losses on Prelude Therapeutics IncorporatedJuly 2025 Volume & AI Driven Price Forecasts - Newser
Prelude Therapeutics Incorporated stock trendline breakdown2025 Winners & Losers & Comprehensive Market Scan Insights - Newser
Why Prelude Therapeutics Incorporated stock attracts strong analyst attentionQuarterly Profit Report & Real-Time Volume Analysis Alerts - Newser
Is Prelude Therapeutics Incorporated trading at a discountTrade Risk Summary & Community Verified Trade Signals - thegnnews.com
Neurizon cites ‘strain’ at FDA as reason for delay on IND hold; Fifty Years’ $126M fund - Endpoints News
Prelude Therapeutics Reports Q2 2025 Financial Results - TipRanks
Prelude Therapeutics Pauses Intravenous SMARCA2 Degrader Development - TipRanks
Prelude Cuts Q2 Losses and Costs 13% - The Motley Fool
Prelude (PRLD) Announces Q2 2025 Results; Presentation Attached | PRLD SEC FilingForm 8-K - Stock Titan
Prelude Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - Yahoo Finance
0.80%
0.72%
자본화:
|
볼륨(24시간):